Accurate assessment of risk factors for nosocomial acquisition of colonization by antibiotic-resistant bacteria (ARB) is often confounded by scarce data on antibiotic use. A 12-month, nested, multicenter cohort study was conducted. Target ARB were methicillin (meticillin)-resistant Staphylococcus aureus (MRSA), vancomycinresistant enterococci (VRE), and ciprofloxacin-resistant Pseudomonas aeruginosa (CR-PA). Nares and rectal swabs were obtained before and after starting antibiotics. Pulsed-field gel electrophoresis was done to define genetic relatedness of the strains. Primary outcomes were (i) the mean time, in days, for acquisition of target ARB colonization in patients previously not colonized; (ii) the rate of acquisition per 1,000 antibiotic-days according to different classes of antibiotics; (iii) the rate of infection caused by the same bacteria as those previously isolated in screening samples; and (iv) the risk factors for ARB acquisition. In total, 6,245 swabs from 864 inpatients were processed. The rate of acquisition was 3%, 2%, and 1% for MRSA, VRE, and CR-PA, respectively. The rate of acquisition of ARB per 1,000 antibiotic-days was 14 for carbapenems, 9 for glycopeptides, and 6 for broad-spectrum cephalosporins and quinolones. The highest rates of acquisition were observed for carbapenems in dialyzed and diabetic patients. Four risk factors were independently associated with acquisition of target ARB: use of carbapenems, age of >70 years, hospitalization for >16 days, and human immunodeficiency virus infection. During the 30-day follow-up, 4 among 42 patients newly colonized by ARB (9%) suffered from an infection due to the same bacteria as those isolated in a previous screening sample. Colonizing and infecting strains from single patients were genotypically identical. Identifying ARB colonization early during antibiotic therapy could target a high-risk hospitalized population that may benefit from intervention to decrease the risk of subsequent nosocomial infections.
The control of nosocomial antibiotic-resistant infections is a public health priority worldwide. Meta-analyses have documented that bloodstream infection caused by methicillin (meticillin)-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum ␤-lactamase-producing Enterobacteriaceae, and multidrug-resistant Acinetobacter baumannii are associated significantly with mortality (7, 9, 11, 24) . Numerous papers have demonstrated that prior antimicrobial drug exposure is a strong risk factor for colonization and infection due to a drug-resistant pathogen (2, 25, 27) . However, the association between antibiotic therapy and the acquisition of antibiotic-resistant bacteria (ARB) is still unclear and is often confounded by scarce data on antibiotic usage. In our opinion, two major questions are still unsolved. When does an antibiotic select colonizing ARB in a hospitalized patient? Is there a direct correlation between hospital antibiotic usage, acquisition of ARB colonization, and subsequent bacterial infection in a single patient? Results from retrospective studies were not able to answer these complex questions. Previous studies were strongly heterogeneous in defining colonization and infection. In particular, the extension of time at risk in single studies ranged from a few days up to 1 year. A few small prospective studies are available (10, 17) . In a double-blind clinical trial, the acquisition of stool colonization with resistant Enterobacteriaceae occurred significantly after treatment with piperacillin-tazobactam (10) .
To the best of our knowledge, no previous hospital-based studies have assessed temporal changes in nasal and intestinal colonization in the predominance of resistant and susceptible bacterial strains in patients after starting antibiotic therapy. Accordingly, the main goals of our study were to compare rates of ARB acquisition in different treatment groups and to define the temporal relationship between the start of antibiotic therapy, the acquisition of new colonization in patients previously not colonized, and the development of a bacterial infection care-associated infections were defined using the Centers for Disease Control and Prevention definitions (12) . All target ARB recovered from surveillance cultures and clinical samples were further characterized for genetic relatedness.
To identify risk factors for the acquisition of target ARB, a nested case-control study was performed. Designation as a case patient was based on whether the patient with negative cultures at baseline acquired a new colonization by target ARB during the follow-up. The control group was composed of patients with negative cultures at baseline and from whom ARB were not isolated. Antibiotic therapy was analyzed until the new colonization in cases and for the duration of treatment among controls.
Microbiological studies. All centers followed the same microbiological protocol. Nasal swabs were streaked onto S. aureus ID and chromID MRSA media (bioMérieux, Marcy l'Etoile, France), which are selective for S. aureus and MRSA, respectively. To detect the presence of VRE and P. aeruginosa, the rectal specimens were plated onto Columbia, chromID VRE, and MacConkey agar plates (bioMérieux). Clinical samples were processed by conventional methods. Identification to the species level and antimicrobial susceptibility testing were carried out with the Vitek 2 system (bioMérieux, Inc, Hazelwood, MO). Conventional manual biochemical methods were used when the automated system provided indeterminate results. Results of susceptibility testing were interpreted in accordance with Clinical Laboratory Standards Institute (CLSI) guidelines (6) . All target ARB recovered from surveillance cultures or clinical samples were stored at Ϫ70°C and shipped to a central laboratory (Siena) for further phenotypic and genotypic characterization. In cases of patients acquiring both susceptible and resistant strains, both isolates were frozen and genotyped. Glycopeptide resistance genotypes were identified by the PCR method as described by Depardieu et al. (8) . Staphylococcal cassette chromosome mec (SCCmec) typing was performed as described by Kondo et al. (18) . Genotyping of MRSA and VRE isolated by macrorestriction analysis through pulsed-field gel electrophoresis (PFGE) was carried out as previously described (28) . Genotyping of P. aeruginosa by PFGE was performed by the method of Römling et al. (23) .
Statistical analysis. Quantitative variables were tested for normal distribution and compared by means of the two-tailed t test. Differences in groups were assessed by use of the 2 test and Fisher's exact test. The precision of relative risk was determined by calculating a 95% confidence interval. A P value less than 0.05 was considered statistically significant. The assessable population for each target organism included all treated patients from whom data from baseline screening and at least one follow-up screening were available. The incidence of colonization was defined by the number of new cases of colonization for 1,000 days of antibiotic therapy. Only patients with a negative baseline (t 0 ) were included in the longitudinal analysis. The length of exposure to antibiotic therapy for patients newly colonized by ARB was defined by the number of days between inclusion in the study (i.e., first screening sample) and the date of the first positive sample. The length of exposure to antibiotic therapy for patients not colonized by ARB was defined by the number of days between inclusion in the study and the date of antibiotic withdrawal. The time-to-event analysis (in days) between inclusion in the study and the acquisition of colonization was done using the Cox proportional hazard regression model, in which the number of days until acquisition of ARB was the dependent variable. Potential risk factors for ARB acquisition were analyzed by univariate analysis. Variables from the univariate analysis with a P value of less than 0.01 were considered for inclusion in multivariate logistic regression analysis. Backward stepwise logistic regression was performed, and the model that was considered biologically plausible and had the lowest Ϫ2-log likelihood ratio was chosen as the final model. Results are presented as multivariate (adjusted) risk ratios. The Hosmer and Lemeshow goodness-of-fit test was used to assess model fit. Statistical analysis was performed using the software program Inter-cooled Stata (Stata Statistical Software, version 8.0).
RESULTS
Patient characteristics. Eight hundred ninety-six patients were asked to participate in the study; 32 of them refused enrollment. A total number of 6,245 samples (3,143 nasal and 3,102 rectal) were collected. The most important epidemiological features of patients included in the study are illustrated in Table 1 . Mean duration of hospitalization (standard deviation [SD]) before baseline screening was 5 days (11 days). The most commonly prescribed antibiotics were broad-spectrum cephalosporins (31%), followed by quinolones (29%) and macrolides Table 2 . Overall, 9,300 days of antibiotic therapy were analyzed. Mean duration of therapy (SD) was 8.6 (6.2) days for carbapenems, 7.9 (6.6) days for broad-spectrum cephalosporins, 9.1 (6.6) days for quinolones, 8.5 (6.4) days for glycopeptides, 8.1 (5.8) days for macrolides, and 8.9 (5.6) days for piperacillintazobactam. Of the 864 patients who had culture screening performed, 47 (5%) had at least one screening sample positive for MRSA, 16 (2%) had at least one screening sample positive for VRE, and 15 (2%) had at least one screening sample positive for CR-PA.
Baseline colonization (t 0 ). Before starting antimicrobial therapy, 140 patients (16%) harbored S. aureus in the nose, 434 patients (50%) harbored Enterococcus species, and 24 patients (3%) harbored P. aeruginosa in rectal samples. At baseline, the prevalence of target ARB was 4%. In particular, the baseline rate was 3%, 1%, and 0.5% for MRSA, VRE, and CR-PA, respectively. Twenty-four percent of patients colonized by ARB at t 0 had at least one course of therapy within the 15 days before their inclusion, for the most part with quinolones.
New colonization in patients with negative results at t 0 . Two hundred eighty-three patients (283/696; 40%) acquired new colonization during the 30-day follow-up. Seventy-four patients acquired colonization with staphylococci (52 with methicillin-susceptible S. aureus and 22 with MRSA), 28 acquired colonization with P. aeruginosa (17 with ciprofloxacin-susceptible P. aeruginosa and 11 with CR-PA), and 10 acquired colonization with VRE. One patient acquired both MRSA and VRE. The rate of acquisition was 3% (22/724), 2% (10/430), and 1% (11/840) for MRSA, VRE, and CR-PA, respectively. A high percentage of new acquisition (40%) was detected within 48 h of the start of antibiotic therapy. MRSA acquisition appeared after a mean (SD) of 8 (4) days (range, 2 to 16), VRE appeared after 6 (6) days (range, 2 to 19), and CR-PA appeard after 9 (8) days (range, 2 to 28) of antibiotic therapy.
The incidence of new colonization by ARB was calculated for 1,000 antibiotic-days. Table 3 shows the incidence of acquisition according to antibiotic classes, length of therapy (stratified by 5, 10, and 15 days), and high-risk classes of patients. The highest risk for ARB acquisition was observed for the use of carbapenems, with 14 new cases for 1,000 antibioticdays. The incidence increased in the presence of the following risk factors: dialysis and diabetes, ICU admission, and cirrhosis. The incidence of acquisition was 9 for glycopeptides, 6 for broad-spectrum to fourth-generation cephalosporins, and 6 for quinolones. For MRSA acquisition, the highest risks were observed for carbapenem and macrolide usage (eight new cases for 1,000 antibiotic-days for both classes).
Infections with target ARB. Follow-up was completed in 85% of included patients. If a patient did not perform the last screening sample, he or she was contacted by telephone, whenever possible, in order to obtain information. During the 30-day follow-up, antibiotics were prescribed by physicians for 145 patients (17%) with suspected bacterial infections. In 82 of those patients (57%), a microbiologically proven bacterial infection was detected. None of the patients suffered from a relapsing disease. Among the microbiologically proven infections, 39 (48%) were caused by P. aeruginosa, 26 (32%) by S. aureus, and 10 (12%) by enterococci. The sites of infection included the lung (40 patients), urine (27 patients), bloodstream (20 patients), and skin and soft tissues (four patients). Fourteen episodes (14/82, 17%) were caused by the same bacterium as that isolated in a previous surveillance sample. In particular, 4 out of 42 (9%) patients with new ARB colonization developed an infection due to the same bacterium ac- ................................................................................ 41 (11)  Pseudomonas aeruginosa...................................................... on July 9, 2017 by guest http://aac.asm.org/ quired after the start of antibiotic therapy. Two infections were due to MRSA (skin and ventilation-associated pneumonia), and two were due to CR-PA (urinary tract infection and pneumonia). The mean interval (SD) between the first positive sample and the appearance of infection was 13 (9) Risk factors for ARB acquisition. A nested case control study was performed to define the inpatients at risk of acquiring ARB colonization among those starting antibiotics. Seven hundred fifteen patients were included: 42 cases and 673 controls. Table 4 shows the main epidemiological and clinical variables in cases and controls. In the multivariate analysis (Table 5) , the use of carbapenems, age of Ͼ70 years, HIV infection, and length of stay (LOS) of Ͼ16 days before enrollment remained significant predictors of subsequent acquisition Molecular analysis. SCCmec analysis showed that 67% of MRSA strains were type I, 17% were type IV, 4% were type II, and 3% were type III. All VRE tested showed the presence of the vanA gene. PFGE analysis of target ARB showed that all strains were genotypically different, except for one strain of CR-PA identified in three patients in Rome and in two patients in Brescia.
Six patients colonized with methicillin-susceptible S. aureus at t 0 acquired colonization with MRSA (5%). Three patients colonized with vancomycin-susceptible enterococci (1%) and two patients colonized with ciprofloxacin-susceptible P. aeruginosa (10%) at baseline acquired VRE and CR-PA, respectively. Eleven patients initially colonized with resistant flora (11/36, 30%) harbored susceptible organisms in a subsequent sample. The PFGE analysis done to compare susceptible and resistant strains isolated in different screening samples in an individual patient did not show any correlation, suggesting that all new ARB colonizations were new acquisitions regardless of colonization with susceptible bacteria. Colonizing and infecting strains in an individual patient were shown to be genotypically identical. Staff screening and patient samples did not show any correlation.
DISCUSSION
This study was designed to assess the acquisition of antibiotic-resistant microorganisms in hospitalized patients after starting antibiotics. Overall, including 864 patients for a total of 6,245 samples, we found that 5% of patients were newly colonized by ARB after starting antibiotic therapy. A significantly high percentage of isolations appeared within 48 h of the start of therapy. This colonization occurred more rapidly for VRE (on average after 6 days of therapy) and later for MRSA and CR-PA (after 9 days of therapy). A small percentage of patients showed an initial colonization by susceptible strains followed by a colonization by resistant strains. The use of carbapenems, age of more than 70 years, HIV infection, and a LOS of more than 16 days before the start of the antibiotic therapy were independently associated with the acquisition of ARB after adjusting for major confounders.
In vitro and in vivo studies have already documented that exposure to carbapenems increases the risk of isolation of ARB (1, 13, 14, 29) . In our study the use of carbapenems was also associated with the highest incidence of colonization for 1,000 antibiotic-days (14 new cases). This value rises in the presence of dialysis, diabetes, ICU admission, and cirrhosis.
Not unexpectedly, an age of more than 70 years and previous LOS of more than 16 days were strongly associated with ARB acquisition. A number of factors contribute to an increased risk of colonization and infection among the elderly population, including alteration in the immune system, malnutrition, and social and economic factors (16, 20, 26) . Older age might also be a marker for other risk factors not covered in our study. Prolonged duration of hospitalization almost doubled the risk for ARB acquisition, probably due to patients' risk factors (having more severe underlying conditions) and hospitalrelated risk factors such as colonization pressure.
Several immunological HIV-related alterations and epidemiological risk factors predispose infected patients to ARB colonization and infection. A recent case control study observed that a low CD4 cell count, a history of multiple hospitalizations, and exposure to beta-lactams were statistically significant risk factors for MRSA bloodstream infection in HIV-infected patients (30) .
Our study showed that 9% of patients newly colonized by ARB developed an infection by the 30-day follow-up. A previous study of ICU patients showed that 25% of patients previously colonized with extended-spectrum beta-lactamaseproducing bacteria had a subsequent extended-spectrum betalactamase-positive clinical culture (15) . The results from the genotyping support the concept that colonizing bacteria provide the subsequent infection. Of course, typing concordance cannot be used to definitively exclude the possibility that the infecting strain originated from other sources such as health care workers or patients not undergoing antibiotic therapy. However, it is important to underline that genotypic analysis did not show any correlation between the patients' strains within the same center. Our data further underline that antibiotic therapy has a role not only in the development of new colonization but also in the emergence of nosocomial infections caused by the same strains. Previous studies have already documented that colonization is a risk factor for antibioticresistant infections (21, 22) , but this is the first study that correlates this event directly to a previous antibiotic therapy cycle.
There were several shortcomings in our study. First, the data set on which we performed our analysis was limited by the small number of patients colonized with ARB. This might have hampered our ability to fully check for possible confounding factors and might have underestimated the role of specific antibiotic or combination therapy. Although the conclusions based on these data are statistically significant, confirmation of our findings in a larger clinical trial would be desirable. In particular, our study was not able to distinguish the effect of monotherapy from that of combination therapy. Data were analyzed for the most commonly used associations such as glycopeptides plus cephalosporins or carbapenems with no significant results. Second, the lack of combined sites of screening and of stool samples might have underestimated the relationship of some antibiotics with gastrointestinal absorption. We cannot exclude the possibility that ARB were already present in the gut or in the nose of the patients and were not detected. Third, intermittent colonization, not detected at study enrollment, might have played a role. Lastly, we did not detect infections after more than 30 days of antibiotic therapy.
Our findings contribute toward a better understanding of the effect of antibiotic therapy on the acquisition of antibioticresistant microorganisms and development of infections in hospitalized patients, although more studies with a greater sample size are needed. The risk of acquiring ARB colonization varies between different classes of antibiotics and is highest for dialysis and diabetes patients after carbapenem usage. The risk associated with a selected antibiotic is also strictly related to the preexisting condition of the patient, length of hospitalization, and age. We believe that the information obtained from prospectively monitoring the colonization status of high-risk patients after starting antibiotics could directly ben- 
